March 2, 2020 10:03 AM ESTUpdated March 3, 04:29 AM

Merck clears PFS endpoint in confirmatory trial for Keytruda in classical Hodgkin lymphoma

Amber Tong

Classical Hodgkin lymphoma was the first blood cancer that Merck’s Keytruda was approved to treat. Three years after that OK arrived — kicking off a spate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Merck clears PFS endpoint in confirmatory trial for Keytruda in classical Hodgkin lymphoma

Amber Tong

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Mer­ck clears PFS end­point in con­fir­ma­to­ry tri­al for Keytru­da in clas­si­cal Hodgkin lym­phoma

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Merck clears PFS endpoint in confirmatory trial for Keytruda in classical Hodgkin lymphoma